COMP <GO>
UTHR vs ABBV // RSI-14 & 200D SMA MOMENTUM
United Therapeutics Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: UTHR 10
— ABBV 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
rsi-technicals
70.1
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 70.20% | +17.70 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 29.00% | -8.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 33.3x | -20.80 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 3.47% | +0.62 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | 24.60% | +22.30 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 6.90% | +35.00 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 8.60% | +2.00 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 5.33 | +17.19 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | UTHR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 70.1 | 72.8 | -2.66 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 113.1x | -95.30 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $513.86B | -$488.40B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | ABBV REV | UTHR GROSS % | ABBV GROSS % | UTHR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $61.16B | 87.9% | 70.2% | $1.04B | $17.82B |
| FY 2024 | $2.88B | $56.33B | 89.2% | 70.0% | $1.08B | $17.83B |
| FY 2023 | $2.33B | $54.32B | 44.0% | 44.0% | $873.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
ABBV // BETA 1.15